Non-Hodgkin Lymphoma: Collaborating With Your Care Team

See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.

Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.

Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.

September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.

After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.

Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.

Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.